Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 5/20 | 0.35 |
| ▸ | THRA | P10827 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449303 | 0.87 | RORC (0.40) | RORCLMNAALDH1A1HTTMAPT | |
| SCHEMBL22959061 | 0.87 | RORC (0.51) | RORCLMNATHRBTHRAALDH1A1 | |
| SCHEMBL24449313 | 0.82 | RORC (0.45) | RORCLMNATHRBTHRAALDH1A1 | |
| SCHEMBL24449959 | 0.81 | RORC (0.41) | RORCTHRBTHRAGAAMAPT | |
| SCHEMBL30558158 | 0.81 | RORC (0.41) | RORCTHRBTHRAGAAMAPT | |
| SCHEMBL30148695 | 0.79 | ALDH1A1 (0.41) | LMNAALDH1A1HTTGAAMAPT | |
| SCHEMBL4965062 | 0.78 | THRB (0.48) | RORCLMNATHRBTHRAALDH1A1 | |
| SCHEMBL24449301 | 0.77 | PDE7A (0.50) | RORCLMNAALDH1A1HTTGAA | |
| SCHEMBL29821957 | 0.74 | MEN1 (0.45) | LMNAALDH1A1HTTGAATDP1 | |
| SCHEMBL4962573 | 0.73 | THRB (0.59) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240730-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116710443-A | 2-pyridones as thyroid hormone receptor modulators | 阿利戈斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| WO-2022099044-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | THRA, THRB, TSHR | RORC 283/4885LMNA 3370/4885THRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.